Lymphoma Clinical Trials in Pittsburgh

Showing 361-380 of 675 trials

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

NCT02519270

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin Lymphoma

Spectrum Pharmaceuticals, Inc62 participantsStarted May 2016

Santa Monica, California, United States • Pittsburgh, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653

The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)

LymphomaAcute Lymphoblastic Leukemia

Bristol-Myers Squibb512 participantsStarted Oct 2015

Phoenix, Arizona, United States • Duarte, California, United States • Loma Linda, California, United States +93 more locations

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Lymphoma Trials in Other Cities

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Double Cord Versus Haploidentical (BMT CTN 1101)

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

A Study of LY3023414 in Participants With Advanced Cancer

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Other Conditions in Pittsburgh